IO Biotech, Inc. IOBT 深 沪

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers Olema Pharmaceuticals (NASDAQ:OLMA) stock increased by 137.7% to $20.2...

11-19 01:06

IO Biotech Presents at Jefferies Global Healthcare Conference

IO Biotech ( ($IOBT) ) has provided an announcement. IO Biotech, Inc. announced...

11-18 19:58

IO Biotech Q3 EPS $(0.13) Beats $(0.34) Estimate

IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.34) by 61.19 percent. This is a 63.89 percent increase over losses of $(0.36) per share from the

11-14 21:11

IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

IO Biotech reported interim results for Phase 3 trial IOB-013 for advanced melanoma, showing clinically relevant progression-free survival (PFS) improvements across subgroups though narrowly missing statistical significance. The company plans to meet with the FDA in December to discuss a potential new Phase 3 registrational trial. IO Biotech also presented pre-clinical data for IO112 and IO170 candidates at the SITC Annual Meeting. The company en...

11-14 13:05

IO Biotech Announces Participation in Upcoming Investor Conferences

11-12 13:30

IO Biotech To Present New Pre-Clinical Data For Next Vaccine Candidate, IO112, And Additional Candidate, IO170, At SITC 2025

Pre-clinical data for IO Biotech's next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted

11-07 22:06

Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

NetworkNewsWire Editorial Coverage NEW YORK, Oct. 27, 2025 /PRNewswire/ -- The global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce t...

10-27 20:30

美股大行评级 | 超配！万事达、Visa、Block获多家机构首予评级；奈飞、德州仪器遭多家机构下调目标价

今日重点评级关注：Canaccord Genuity：维持ATAI Life Sciences"买入"评级，目标价从11美元升至14美元；麦格理：维持Cleanspark"跑赢大市"评级，目标价从20美元升至30美元

10-23 10:06

IO Biotech Phase 3: Cylembio Plus KEYTRUDA Extends Median PFS To 19.4 Months In First-Line Advanced Melanoma, Showing Clinically Meaningful Improvement Despite Narrow Miss On Statistical Significance

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS)

10-20 14:48

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

IO Biotech's Phase 3 trial shows Cylembio plus pembrolizumab achieves 19.4-month median progression-free survival (mPFS) vs 11.0 months with pembrolizumab alone in advanced melanoma, narrowly missing statistical significance. Subgroup analyses show consistent PFS improvements across PD-L1-negative, BRAF V600-mutated, and elevated LDH patients. The combination is well-tolerated, with no added systemic toxicity. Final Phase 2 basket trial data in N...

10-20 06:30